Bayer (BAYRY)
(Delayed Data from OTC)
$8.04 USD
-0.05 (-0.62%)
Updated Sep 19, 2025 03:59 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Bayer Aktiengesellschaft has a PEG ratio of 3.74 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.52.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BAYRY 8.04 -0.05(-0.62%)
Will BAYRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
Other News for BAYRY
Oppenheimer maintains bullish stance on Corteva following split reports
Oppenheimer maintains bullish stance on Corteva following split reports
Morgan Stanley says Corteva may want to get out in front of ag landscape changes
Morgan Stanley says Corteva may want to get out in front of ag landscape changes
UBS Keeps Their Hold Rating on Bayer (0P6S)